Induced Pluripotent Stem Cells (iPSCs)
Cyagen’s iPSC services provide high-efficiency reprogramming, precise gene editing, and optimized differentiation for disease modeling, drug discovery, and regenerative medicine.
Optimized Differentiation
≥95% marker expression for high-purity cells.
Advanced Gene Editing
Optimized HDR up to 50%, KO efficiency 90%.
Efficient Reprogramming
Non-integrating method with 99% success rate.
Overview
Workflow
FAQs
Overview
Comprehensive iPSC Solutions
Cyagen provides comprehensive iPSC solutions designed to support various research applications, including iPSC reprogramming, gene editing, and directed differentiation.
— For iPSC reprogramming, we generate high-quality iPSC lines from somatic cells using non-integrating methods, ensuring genetic stability. Each iPSC line undergoes pluripotency and karyotype validation to meet rigorous research standards.
— Our iPSC gene editing services enable precise genetic modifications, including knockout, knock-in, and point mutations. With our optimized HDR technology, we achieve up to 50% efficiency, enhancing the accuracy and success rate of genome edits.
— For iPSC differentiation, we provide specialized cell models, including neurons, blood cells, and liver organoids, tailored for disease research and drug development. Each model is validated through immunofluorescence and qPCR to ensure functionality and reproducibility.
— For iPSC reprogramming, we generate high-quality iPSC lines from somatic cells using non-integrating methods, ensuring genetic stability. Each iPSC line undergoes pluripotency and karyotype validation to meet rigorous research standards.
— Our iPSC gene editing services enable precise genetic modifications, including knockout, knock-in, and point mutations. With our optimized HDR technology, we achieve up to 50% efficiency, enhancing the accuracy and success rate of genome edits.
— For iPSC differentiation, we provide specialized cell models, including neurons, blood cells, and liver organoids, tailored for disease research and drug development. Each model is validated through immunofluorescence and qPCR to ensure functionality and reproducibility.
Explore Ready-to-Use Mouse Models
Discover over 18,000 validated mouse strains—including knockout, conditional knockout, and humanized models—covering 20+ research areas such as oncology, neurology, and metabolism. All models are supported by detailed genotype data and guaranteed quality, helping you fast-track discovery with confidence.
You Might Also Be Interested In
Knockout Cell Lines Library
Browse validated human KO cell lines by gene or cell type
Tumor Cell Lines Library
Access characterized human tumor lines by cancer type or genetic status.
Cell Immunotherapy CRO Platform
CAR-T/NK development with custom vectors, models, and in vivo validation
Targeted Gene Editing
AI-enhanced HDR technology for precise in vivo genome engineering
MouseAtlas Model Library
Search and access curated genetically engineered mouse strains
AAV Vectors Library
Search and order AAVs by serotype, gene, or function
Workflow
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to
you with detailed
information.
Phone Number
Main Area of Research
How did you hear about us?
Service ID
Service
Sample Type
Additional Comments
Workflow and Delivery
Cyagen provides a streamlined, high-efficiency workflow for iPSC
development, from reprogramming and gene editing to directed
differentiation. Our optimized processes ensure high success rates,
rigorous quality control, and fast turnaround times to support your
research needs.
{{ item.title }}
iPSC Reprogramming
iPSC Reprogramming
Cyagen utilizes advanced somatic cell reprogramming technology to reprogram
somatic cells collected from blood samples, generating high-quality human induced
pluripotent stem cells (hiPSCs) with a success rate of up to 99%. We employ a robust,
non-integrating episomal plasmid reprogramming method, ensuring downstream experiments
remain completely unaffected. Furthermore, our standardized operating procedures are
compatible with various culture systems, enabling the large-scale production of high-purity
cells.
Deliverables & QC
| Type | Service | Deliverables | Quality Control (QC) | Turnaround Time | Action |
|---|---|---|---|---|---|
| Reprogramming | iPSC Reprogramming Service | 1 iPSC clone (2 vials/clone, 1×10⁶ cells/vial), Project report | Cell morphology, STR profiling (PBMCs and iPSCs), Karyotyping, Immunofluorescence (OCT4 and NANOG), Flow cytometry (SSEA4/TRA-1-81), Sterility & Mycoplasma testing, In vitro three germ layer differentiation (Optional), Teratoma formation (Optional) | From 12 weeks | |
| iPSC Characterization | iPSC Characterization Service | Characterization report | Cytology testing, Microbiological testing, iPSC marker gene detection, Genetic stability analysis, Differentiation potential assay, Self-renewal capacity assay | From 2 weeks |
Service Process
Advantages of Our iPSC Reprogramming Services
- Stem Cell Experts: Backed by nearly 20 years of experience in stem cell research and a comprehensive, research-grade stem cell bank.
- Quality Assurance: Premium culture media and standardized operating procedures. Robust, non-integrating reprogramming protocols.
- Rapid Turnaround: Delivery of Passage 10 (P10) clones in as fast as 12 weeks. On-time delivery rate ≥ 99%.
- Ph.D.-Level Technical Support: Dedicated project management and expert technical support from Ph.D. scientists.
iPSC Reprogramming Service Content
1. iPSC Generation Process
Figure 1. Morphological illustration of cells at days 3, 5,
9, and 11–20 during iPSC clone generation.
Figure 2. Schematic of vector-free iPSC generation,
including clone picking, purification, and expansion to P10.
2. iPSC Characterization
A
B
C
D
E
Figure 3. (A) Morphology of an iPSC clone. iPSCs typically grow in tightly packed
colonies with clear, well-defined borders. (B) Immunofluorescence staining for iPSC-specific
markers (NANOG, OCT4). (C) Flow cytometry analysis of iPSC-specific surface markers (SSEA4,
TRA-1-81). (D) iPSC karyotyping. (E) iPSC STR profiling.
3. iPSC Differentiation Potential Assessment
A
B
C
Figure 4. (A) qPCR analysis of three germ layer marker gene expression. (B)
Immunofluorescence staining of three germ layer marker genes. (C) Teratoma formation
assay
for in vivo validation of three germ layer differentiation.
iPSC Gene Editing
iPSC Gene Editing
Cyagen features a well-established and robust gene editing platform backed by
experience from over 10,000 gene editing projects and a proven track record of
successful iPSC applications. Supported by the Rare Disease Data Center RNA splicing model
for efficient screening of WB-validated protein-deficient clones. Leveraging the Cell
iGeneEditor™ System, we routinely execute diverse strategies including gene knockouts (KO),
gene knock-ins (KI), point mutations (PM), and stable cell line generation, achieving
editing efficiencies of up to 90-95%. Our services are highly applicable for disease
mechanism research, drug screening platform development, and cell therapy applications,
supporting disease modeling, drug discovery, and translational research.
Deliverables & QC
| Type | Service | Deliverables | Quality Control (QC) | Turnaround Time | Action |
|---|---|---|---|---|---|
| Gene-Edited iPSC Lines | Gene Knockout (KO) | 1 monoclonal cell line and 1 wild-type (WT) control iPSC line (2 vials/clone, 1×10⁶ cells/vial); Project report | PCR and Sanger sequencing, Immunofluorescence (IF), Bright-field microscopy, Sterility & Mycoplasma testing | From 8 weeks | |
| Point Mutation (PM) | From 8 weeks | ||||
| Gene Knock-in (KI) | From 12 weeks | ||||
| Stable iPSC Lines | Knockdown (KD) Stable Cell Line | Stable cell line and control cell line (2 vials/clone, 1×10⁶ cells/vial); Project report | qPCR, Immunofluorescence (IF), Bright-field microscopy, Sterility & Mycoplasma testing | Cell Pool: From 9 weeks Monoclone line: From 13 weeks |
|
| Overexpression (OE) Stable Cell Line | Cell Pool: From 8 weeks + Gene Synthesis Monoclone line: From 12 weeks + Gene Synthesis |
iPSC Gene Editing Service Workflow
- Gene lethality/homology analysis
- AI-assisted design strategy
- Cell iGeneEditor™ System
- RNP delivery
- Optimized α-donor
- High-efficiency electroporation system
- Polyclonal analysis technology
- Optimized monoclonal generation process
- Monoclonal screening and analysis technology
- Sanger sequencing and IF
- Sterility & Mycoplasma testing
- qPCR/WB/FC/Karyotyping/Off-target (Optional)
Advantages of Our iPSC Gene Editing Services
- Stem Cell Experts: Nearly 20 years of stem cell and gene editing experience, possessing a comprehensive research stem cell bank.
- Quality Assurance: Proprietary α-donor vector HDR system with up to 87% HDR efficiency, higher than typical industry benchmarks, delivering homozygous clones. RNP delivery improves gRNA cleavage efficiency and transfected cell viability while reducing off-target effects, with KO efficiency up to 95%. Premium culture media and standardized operations; quality control far exceeds industry standards.
- Rapid Turnaround: Custom projects delivered in as fast as 8 weeks, with an on-time delivery rate ≥ 99%.
- AI-Assisted Design: The Cell iGeneEditor™ System supports multiple strategies, yielding editing efficiencies of over 90%. The RDDC-developed RNA splicing model tool facilitates the robust screening of WB-negative clones.
- Ph.D.-Level Technical Support: Dedicated project management and expert technical support from Ph.D. scientists.
iPSC Gene Editing Case Studies
1. EGFP Knock-in at the AAVS1 Safe Harbor Locus in iPSCs
A
B
C
D
E
Figure 1. (A) Strategy for iPSC-AAVS1-EGFP construction; (B) Sanger
sequencing
confirms successful EGFP knock-in at the target locus; (C) Fluorescence microscopy shows
cells marked with EGFP knock-in exhibiting bright EGFP fluorescence; (D) G-banding karyotype
analysis after cell culture shows a normal count of 46 chromosomes with no obvious
structural abnormalities; (E) Immunofluorescence of pluripotency markers (NANOG, OCT4, and
SOX2) in EGFP knock-in iPSCs all show positive signals, indicating the knocked-in cells
possess stemness.
2. iPSC CTCF Enhancer (>10kb) Knockout Cell Line Generation (Commissioned by Ophthalmic Center, Sun Yat-sen University)
The CTCF enhancer was knocked out in induced pluripotent stem cells (iPSCs) via gene editing technology. By electroporating RNP complexes into iPSCs, a >10kb CTCF enhancer was successfully knocked out.
A
B
C
Figure 2. (A) Strategy for iPSC CTCF enhancer knockout construction; (B) PCR
validation of the knockout clone: F1R2 amplification yields a short band of ~1kb, with no
bands amplified at the junction ends; (C) Sanger sequencing confirms successful knockout,
with a 10,604 bp deletion in Allele 1 and a 10,605 bp deletion in Allele 2.
iPSC Directed Differentiation
iPSC Directed Differentiation
Directed differentiation involves guiding iPSCs into target somatic cell
types—such as neurons, cardiomyocytes, and hepatocytes—under specific experimental
conditions and cell culture systems. Cyagen provides diverse disease modeling and drug
screening platforms, offering premium, highly customizable services for researchers.
iPSC Directed Differentiation Services & Deliverables
| Service | Deliverables | Quality Control (QC) | Turnaround Time | Action |
|---|---|---|---|---|
| NPC (Neural Progenitor Cell) Differentiation | 5E6 Cryopreserved cells | IF(SOX2/PAX6/Nestin) | 3-4 weeks | |
| Motor Neuron Differentiation | 3E6 Motor neuron progenitor cryopreserved cells | IF(MNP Oligo2/MNS CHAT) | 6-8 weeks | |
| Cortical Neuron Differentiation | 2E6 Cortical neuron progenitor cryopreserved cells | IF (NeuN/MAP) | 6-8 weeks | |
| Dopaminergic Neuron Differentiation | 2E6 Dopaminergic Neuron progenitor cryopreserved cells | IF (TH/TUJ1) | 8-10 weeks | |
| RPE (Retinal Pigment Epithelium) Differentiation | 2E6 RPE cryopreserved cells | IF (MiTF/ZO-1/RPE65) | 7-9 weeks | |
| HPC (Hematopoietic Progenitor cells) Differentiation | 2E6 HPC cryopreserved cells | qPCR, flow cytometry, IF | 3-4 weeks |
Ready-to-Use iPSC Differentiated Cells
| Product Name | Service ID | Genetic Modification | Disease Area/Application | Turnaround Time | Action |
|---|---|---|---|---|---|
| iPSC-CN (Cortical neurons) | SY-iCN-00001 | — | Neurology | 2-3 weeks | |
| iPSC-DA (Dopaminergic neurons) | SY-iD-00001 | — | Neurology | 2-3 weeks | |
| iPSC-MNP (Motor neurons) | SY-iM-00001 | — | Neurology | 2-3 weeks | |
| iPSC-NPC (Neural progenitor cells) | SY-iN-00001 | — | Neurology | 2-3 weeks | |
| iPSC-RPE (Retinal pigment epithelial cells) | SY-iR-00001 | — | Ophthalmology | 2-3 weeks | |
| iPSC-RPE-PRF31 KO | SY-iR-00002 | PRPF31 knockout | Ophthalmology | 2-3 weeks | |
| iPSC-HPC (Hematopoietic progenitor cells) | SY-iH-00001 | — | Hematology | 2-3 weeks | |
| iPSC-MSC (Mesenchymal stem cells) | SY-iMS-00001 | — | Regenerative medicine | 2-3 weeks |
Note: All products listed above are provided as differentiated
cells. Please inquire for pricing and ordering details.
iPSC Directed Differentiation Case Studies
1. Neural Progenitor Cell (NPC) Differentiation — Neurological Disease Modeling
A
B
Figure 1. (A) NPC differentiation workflow. (B) Morphology of differentiated cells.
(C) Immunofluorescence detection of NPC-specific markers (SOX2, PAX6, and Nestin).
2. Motor Neuron (MN) Differentiation — Neurological Disease Modeling (e.g., ALS)
A
B
C
D
Figure 2. (A) MN differentiation workflow. (B) Morphology of cells at days 12, 22,
and 28 of differentiation. (C) Immunofluorescence detection of motor neuron progenitor
(MNP)-specific markers (Olig2, TUJ1). (D) Immunofluorescence detection of MN-specific
markers (ChAT, TUJ1).
3. Retinal Pigment Epithelium (RPE) Cell Differentiation — Ophthalmic Disease Modeling
A
B
C
D
E
Figure 3. (A) RPE differentiation workflow. (B) Morphology of cells at days 6, 16,
and 42 of differentiation. (C) Immunofluorescence detection of RPE-specific markers (ZO-1,
MITF). (D) qPCR analysis of RPE-specific markers (ZO-1, MITF). (E) Detection of RPE
secretory factors (VEGF, PEDF).
4. Hematopoietic Stem Cell (CD34+) Differentiation — Applicable for Blood Lineage Cell
Differentiation (e.g., NK, T cells)
A
B
C
Figure 4. (A) CD34+ hematopoietic stem/progenitor cell differentiation workflow. (B)
Morphology of hematopoietic progenitor cells (HPCs). (C) Flow cytometry analysis of HPC-specific
markers (CD34, CD43).
FAQs
Frequently Asked Questions (FAQs)
How do iPSCs differ from ESCs?
iPSCs avoid ethical concerns while offering similar differentiation potential.
Can iPSCs be used for personalized medicine?
Yes, patient-derived iPSCs enable autologous cell therapy research.
How do you ensure iPSC genetic stability?
We use episomal vectors and conduct karyotype & STR analysis.
What gene editing strategies do you offer?
We support knockout, knock-in, point mutations, and stable expression.
How do you validate differentiation outcomes?
Immunofluorescence, flow cytometry, and qPCR are used for confirmation.
Citation Database
Molecular Therapy: Methods & Clinical Development, March, 2025
Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing
【Other】
Gut, February, 2025
E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression
【Other】
Cell Death & Disease, February, 2025
Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage
【Other】
Molecular Therapy, February, 2025
Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer
【Other】
Request a Custom Cell Line Consultation
Tell us about your cell line project needs. Our specialists are ready to support your research with tailored solutions.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
